Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hypersensitivity × ZD4054 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 4 Neoplasm Metastasis 3 Rectal Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Hypersensitivity 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

iniparib 2 Poly(ADP-ribose) Polymerase Inhibitors 2 amminedichloro(2-methylpyridine)platinum(II) 1 ZD4054 1 Rituximab 1 Paclitaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00929162 2012-08-07

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

AstraZeneca

Phase 2 Terminated

120 enrolled 8 charts

Hypersensitivity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡